LEVBIO Stock Overview
Designs, develops, and distributes diagnostics products in the Nordic region and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Level Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.42 |
| 52 Week High | kr0.79 |
| 52 Week Low | kr0.12 |
| Beta | 0.053 |
| 1 Month Change | 36.36% |
| 3 Month Change | 50.00% |
| 1 Year Change | -35.58% |
| 3 Year Change | -72.58% |
| 5 Year Change | 5.00% |
| Change since IPO | -96.64% |
Recent News & Updates
Recent updates
Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?
Jun 02
Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?
Feb 10I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease
Nov 03AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected
Aug 18Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?
Mar 07Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?
Nov 22Shareholder Returns
| LEVBIO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 45.8% | 1.2% | -0.9% |
| 1Y | -35.6% | 3.9% | 14.2% |
Return vs Industry: LEVBIO underperformed the Swedish Life Sciences industry which returned 3.9% over the past year.
Return vs Market: LEVBIO underperformed the Swedish Market which returned 14.2% over the past year.
Price Volatility
| LEVBIO volatility | |
|---|---|
| LEVBIO Average Weekly Movement | 29.3% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: LEVBIO's share price has been volatile over the past 3 months.
Volatility Over Time: LEVBIO's weekly volatility has increased from 23% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 13 | Joakim Granemo | www.alphahelix.com |
Level Bio AB (publ) designs, develops, and distributes diagnostics products in the Nordic region and internationally. The company distributes equipment; consumables and reagents for molecular biology; and research and diagnostic products in Sweden and the Nordics. It also develops, produces, and sells products for genetic fetal diagnostics, as well as genetic miscarriage and infertility diagnostics products.
Level Bio AB (publ) Fundamentals Summary
| LEVBIO fundamental statistics | |
|---|---|
| Market cap | kr26.63m |
| Earnings (TTM) | -kr11.38m |
| Revenue (TTM) | kr23.20m |
1.1x
P/S Ratio-2.3x
P/E RatioIs LEVBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LEVBIO income statement (TTM) | |
|---|---|
| Revenue | kr23.20m |
| Cost of Revenue | kr12.12m |
| Gross Profit | kr11.08m |
| Other Expenses | kr22.46m |
| Earnings | -kr11.38m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 47.76% |
| Net Profit Margin | -49.04% |
| Debt/Equity Ratio | 0% |
How did LEVBIO perform over the long term?
See historical performance and comparison